Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 30;5(2):e114.
doi: 10.2196/resprot.5757.

Diagnosis of Basal Cell Carcinoma by Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial

Affiliations

Diagnosis of Basal Cell Carcinoma by Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial

Malou Peppelman et al. JMIR Res Protoc. .

Abstract

Background: Skin cancer, including basal cell carcinoma (BCC), has become a major health care problem. The limitations of a punch biopsy (at present the gold standard) as diagnostic method together with the increasing incidence of skin cancer point out the need for more accurate, cost-effective, and patient friendly diagnostic tools. In vivo reflectance confocal microscopy (RCM) is a noninvasive imaging technique that has great potential for skin cancer diagnosis.

Objective: To investigate whether in vivo RCM can correctly identify the subtype of BCC and to determine the cost-effectiveness of RCM compared with punch biopsy (usual care).

Study design: Randomized controlled multicenter trial.

Methods: On the basis of 80% power and an alpha of 0.05, 329 patients with lesions clinically suspicious for BCC will be included in this study. Patients will be randomized for RCM or for a punch biopsy (usual care). When a BCC is diagnosed, surgical excision will follow and a follow-up visit will be planned 3 months later. Several questionnaires will be filled in (EQ-5D, EQ-5D VAS, iMTA PCQ, and TSQM-9). We will perform statistical analysis, cost-effectiveness, and patient outcome analysis after data collection.

Results: This research started in January 2016 and is ethically approved. We expect to finish this study at the end of 2018.

Conclusions: In this study, we will investigate whether RCM is at least as good in identifying BCC subtypes as conventional pathological investigation of skin biopsies. Anticipating that RCM is found to be a cost-effective alternative, it saves on direct medical consumption like labor of the pathologist and other medical personnel as well as materials related to treatment failure with at least equal effectiveness.

Trial registration: Clinicaltrials.gov NCT02623101; https://clinicaltrials.gov/ct2/show/NCT02623101 (Archived by WebCite at http://www.webcitation.org/6id54WQa2).

Keywords: basal cell carcinoma; cost effectiveness; diagnosis; reflectance confocal microscopy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Scheme of randomization. Two randomization arms are designed. After inclusion, a patient with a clinical diagnosis of BCC (diagnosis à vue) will be randomized over the two arms. One arm contains the standard procedure of a biopsypunch biopsy, the other arm contains the diagnostic tool to be investigated: RCM. A punch biopsy will also be obtained when there is no suspicion of a BCC using RCM.

Similar articles

Cited by

References

    1. Flohil SC, de VE, Neumann H A Martino. Coebergh JW, Nijsten T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol. 2011 Jan;91(1):24–30. doi: 10.2340/00015555-1009. http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1009 - DOI - PubMed
    1. Flohil SC, van der Leest Robert J T. Dowlatshahi EA, Hofman A, de VE, Nijsten T. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol. 2013 Aug;133(8):1971–8. doi: 10.1038/jid.2013.134. http://linkinghub.elsevier.com/retrieve/pii/S0022-202X(15)36356-9 S0022-202X(15)36356-9 - DOI - PubMed
    1. Flohil SC, Seubring I, van Rossum Michelle M. Coebergh JW, de VE, Nijsten T. Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol. 2013 Apr;133(4):913–8. doi: 10.1038/jid.2012.431. http://linkinghub.elsevier.com/retrieve/pii/S0022-202X(15)36169-8 S0022-202X(15)36169-8 - DOI - PubMed
    1. Housman TS, Feldman SR, Williford PM, Fleischer AB, Goldman ND, Acostamadiedo JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003 Mar;48(3):425–9. doi: 10.1067/mjd.2003.186.S019096220261775X - DOI - PubMed
    1. Madan V, Lear JT, Szeimies R. Non-melanoma skin cancer. Lancet. 2010 Feb 20;375(9715):673–85. doi: 10.1016/S0140-6736(09)61196-X.S0140-6736(09)61196-X - DOI - PubMed

Associated data

LinkOut - more resources